Debunking the Top 5 Myths about Psilocybin
Psilocybin has received a lot of attention in recent years. While there is still much to learn about its potential therapeutic benefits and risks, one thing is clear – there are many misconceptions surrounding psilocybin and magic mushrooms. Here we will debunk the top five myths about psilocybin to help inform readers on this important topic.
Myth #1: Psilocybin is Highly Addictive
This myth is simply not true. Research suggests that psilocybin does not have any addictive properties and may even be beneficial for those with substance use disorders. For example, a study published in JAMA Psychiatry found that participants who used psilocybin reported a significant decrease in their cravings for alcohol and other drugs after just one session. [1] Furthermore, a systematic review of the literature concluded that there is no evidence to suggest that psilocybin causes physical or psychological dependence. [2]
Myth #2: Psilocybin Causes Permanent Mental Health Problems
This myth has been debunked by numerous studies which have found that psilocybin can actually be beneficial for mental health. For example, a study conducted at John Hopkins University showed that two doses of psilocybin administered seven days apart produced long-term improvements in mood and anxiety symptoms among individuals with major depression. [3] Additionally, a systematic review of the literature concluded that there is no evidence to suggest that psychedelics like psilocybin increase the risk of developing mental health problems.
Myth #3: Psilocybin is a Gateway Drug
This myth has been widely debunked by scientific research, which shows that psychedelics such as psilocybin are not associated with an increased risk of using other illicit drugs or developing substance use disorders. In fact, some research suggests that psychedelics may actually reduce the risk of using other illicit drugs or developing substance use disorders by helping individuals gain insight into their own behavior and motivations.
Myth #4: Psilocybin is Dangerous and Unsafe to Use
This myth has been debunked by studies that have found that when taken under proper supervision, psychedelic substances like psilocybin are generally safe and well tolerated. A review of the literature concluded that while psychedelics can produce temporary adverse effects such as nausea, dizziness, anxiety, and confusion during a trip, these effects tend to be mild to moderate in severity and resolve within 24 hours without any long-term consequences. [4] Additionally, when taken under proper medical supervision, it appears that psychedelics do not pose any serious risks to physical or mental health.
Myth #5: Psilocybin is Illegal Everywhere and Has No Medical Value
This myth could not be further from the truth. While it’s true that psilocybin remains illegal in most countries around the world – including the United States – it’s also true that numerous clinical trials have demonstrated its potential therapeutic benefits for treating conditions such as depression, anxiety, and addiction. Furthermore, several countries, including Canada, have recently legalized medical access to psychedelic substances such as psilocybin for certain conditions.
Despite the popular misconceptions about its safety profile and legal status – psychedelic substances like psilocybin have demonstrated promising therapeutic benefits when taken under proper medical supervision. It’s important to remember, however – they remain illegal in most countries around the world, so if you’re considering using them – make sure you do your research first and work with an approved healthcare provider.
At Psychly, we are committed to upholding the highest standards in our content creation process. We strive to ensure that all statements presented in our articles are supported by reliable, high-quality sources, such as peer-reviewed studies and reputable academic journals.
- The Psychly Team
- Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953–962. doi:10.1001/jamapsychiatry.2022.2096
- Goel DB, Zilate S. Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus. 2022 Oct 12;14(10):e30214. doi: 10.7759/cureus.30214. PMID: 36381758; PMCID: PMC9650681.
- Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481–489. doi:10.1001/jamapsychiatry.2020.3285
- Tupper, K., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: A re-emerging therapeutic paradigm. Canadian Medical Association Journal, 187(14), 1054-1059. doi:10.1503/cmaj.141124